BRENDA home
History
Information on EC 2.1.1.100 - protein-S-isoprenylcysteine O-methyltransferase
for references in articles please use BRENDA:EC2.1.1.100Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
EC Tree
2.1.1.100 protein-S-isoprenylcysteine O-methyltransferaseIUBMB Comments
C-terminal S-geranylgeranylcysteine and S-geranylcysteine residues are also methylated, but more slowly.
Specify your search results
Word Map
- 2.1.1.100
- n-acetyl-s-farnesyl-l-cysteine
- cysmethynil
- medicine
- a-factor
- aax
- ste24p
-
carboxylmethylation
- n-acetyl-s-geranylgeranyl-l-cysteine
-
ras-driven
- analysis
- biotechnology
- pharmacology
- drug development
The expected taxonomic range for this enzyme is: Eukaryota, Bacteria, Archaea
Reaction Schemes
Synonyms
farnesyl cysteine C-terminal methyltransferase, farnesyl-protein carboxymethyltransferase, farnesylated protein C-terminal O-methyltransferase, Icmt, isoprenylated protein methyltransferase, isoprenylcysteine carboxyl methyltransferase, isoprenylcysteine carboxylmethyltransferase, isoprenylcysteine carboxylmethyltransferase Ste14p, isoprenylcysteine methylesterase, methyltransferase, protein C-terminal farnesylcysteine O-, 
more
topPlease wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYNONYM 
ORGANISM
UNIPROT
COMMENTARY 
LITERATURE
farnesyl cysteine C-terminal methyltransferase
-
-
-
-
farnesyl-protein carboxymethyltransferase
-
-
-
-
farnesylated protein C-terminal O-methyltransferase
-
-
-
-
Icmt
isoprenylated protein methyltransferase
-
-
-
-
isoprenylcysteine carboxyl methyltransferase
isoprenylcysteine carboxylmethyltransferase
methyltransferase, protein C-terminal farnesylcysteine O-
-
-
-
-
prenylated protein methyltransferase
-
-
-
-
protein S-farnesylcysteine C-terminal methyltransferase
-
-
-
-
S-farnesylcysteine methyltransferase
-
-
-
-
Icmt
-
-
isoprenylcysteine carboxyl methyltransferase
-
-
isoprenylcysteine carboxyl methyltransferase
-
-
isoprenylcysteine carboxylmethyltransferase
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION
REACTION DIAGRAM
COMMENTARY
ORGANISM
UNIPROT
LITERATURE
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
kinetic mechanism
-
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
ordered bi bi mechanism, S-adenosyl-L-methionine binds first, S-adenosyl-L-homocysteine departs last
-
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine = S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
REACTION TYPE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
methyl group transfer
-
-
-
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PATHWAY SOURCE
PATHWAYS
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SYSTEMATIC NAME
IUBMB Comments
S-adenosyl-L-methionine:protein-C-terminal-S-farnesyl-L-cysteine O-methyltransferase
C-terminal S-geranylgeranylcysteine and S-geranylcysteine residues are also methylated, but more slowly.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
CAS REGISTRY NUMBER
COMMENTARY
130731-20-3
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBSTRATE
PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
Reversibility
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
S-adenosyl-L-methionine + (RhoAA) C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + (RhoA) C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + 4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + biotin-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + biotin-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C10-Diazirine)-OH
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C5-m-BP)-OH
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + biotin-Peg4-YIIKGVFWDPAC(Fr)-OH
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + biotin-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + biotin-S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + farnesylated and Rce1-proteolyzed K-Ras protein
?
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-(3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2Z,6E,10-trien-1-yl)-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-(3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2Z,6E,10-trien-1-yl)-L-cysteine methyl ester
-
relatively good substrate for the human Icmt enzyme
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-(E)-geranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-(E)-geranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-3,3-dimethylalkyl-L-cysteine
S-adenosyl-L-homocysteine + S-methyl N-acetyl-S-3,3-dimethylalkyl-L-cysteine
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-all trans-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-all trans-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine methyl ester
-
no activity with + N-acetyl-S-geranylgeranyl-L-cysteinyl-S-geranylgeranyl-L-cysteine
-
?
S-adenosyl-L-methionine + N-acetyl-S-trans,trans-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-trans,trans-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine methyl ester
S-adenosyl-L-methionine + N-biotinyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-biotinyl-S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + N-biotinyl-S-farnesyl-L-cysteine peptide
S-adenosyl-L-homocysteine + biotin S-farnesyl-L-cysteine peptide methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + Ras2p
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
S-adenosyl-L-homocysteine + ?
S-adenosyl-L-methionine + S-[(2E,6E)-farnesyl]-3-sulfanylpropanoic acid
S-adenosyl-L-homocysteine + methyl S-[(2E,6E)-farnesyl]-3-sulfanylpropanoate
-
-
-
-
?
S-adenosyl-L-methionine + S-[(2E,6E)-farnesyl]-sulfanylacetic acid
S-adenosyl-L-homocysteine + methyl S-[(2E,6E)-farnesyl]-sulfanylacetate
-
-
-
-
?
S-adenosyl-L-methionine + yeast a-factor mating pheromone C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + yeast a-factor mating pheromone C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosylmethionine + N-((benzoylglycyl)glycyl)-S-farnesyl-L-cysteine
S-adenosylhomocysteine + N-((benzoylglycyl)glycyl)-S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-(benzoylglycyl)-S-farnesyl-L-cysteine
S-adenosylhomocysteine + N-(benzoylglycyl)-S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-D-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-D-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
S-adenosylmethionine + N-acetyl-S-3,3-dimethylallyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-3,3-dimethylallyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-isobutyryl-S-farnesyl-L-cysteine
S-adenosylhomocysteine + N-isobutyryl-S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-isovaleryl-S-farnesyl-L-cysteine
S-adenosylhomocysteine + N-isovaleryl-S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + S-decyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-decyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
S-adenosylmethionine + S-geranyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-geranyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-geranylgeranyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-geranylgeranyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-octyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-octyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-pentadecyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-pentadecyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-tridecyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-tridecyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosyl-L-methionine + (RhoAA) C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + (RhoA) C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + (RhoAA) C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + (RhoA) C-terminal S-farnesyl-L-cysteine methyl ester
-
the enzyme modulates endothelial monolayer per meability by altering RhoA carboxyl methylation and activation, thus changing the organization of intercellular junctions. Carboxy methylation of RhoA may modulate endothelial barrier function
-
-
?
S-adenosyl-L-methionine + 4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + 4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + biotin-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + biotin-S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + biotin-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + biotin-S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
?
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-farnesyl-L-cysteine methyl ester
-
isoprenoid moiety as a key substrate recognition element for Icmt
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-farnesyl-L-cysteine methyl ester
-
isoprenoid moiety as a key substrate recognition element for Icmt
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
no activity with N-acetyl-S-trans-geranyl-L-cysteine
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-geranylgeranyl-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-geranylgeranyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine methyl ester
-
-
-
-
ir
S-adenosyl-L-methionine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine
S-adenosyl-L-homocysteine + N-acetyl-S-[(2E,6E)-farnesyl]-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-biotinyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-biotinyl-S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + N-biotinyl-S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + N-biotinyl-S-farnesyl-L-cysteine methyl ester
-
-
S-adenosyl-L-homocysteine is the final product released
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
21000-24000 Da GTP-binding proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
methylation of a 23000 Da small G protein is indicated
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
fusion protein of heat-inducible ubiquitin and the 11 C-terminal amino acid sequence of Ha-ras protein
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
gamma-subunit of heterotrimeric G-proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
ras-proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
ras-proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
enzyme can methylate both peptides and proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
methyl esterification of proteins containing a C-terminal-CXXX sequence requires not only the removal of the 3 terminal amino acids but the isoprenylation of the sulfhydryl group as well
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
carboxyl methylation may play a role in the regulation of receptor mediated signal transduction processes in eukaryotic cells
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
reversible methylation of ras-proteins may play an important role in the modulation of their signaling properties
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
ras-proteins
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
a-factor, Ras1 and Ras2
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
a-factor mating pheromone, Ras1 and Ras2 are putative substrates of the enzyme
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
the protein is involved in posttranslational modifications of Ras proteins
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosyl-L-methionine + S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
S-adenosyl-L-homocysteine + ?
-
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosylmethionine + N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosylhomocysteine + N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
recombinant enzyme: 50fold higher activity than with N-acetyl-S-geranylgeranyl-L-cysteine, native enzyme: 40fold higher activity than with N-acetyl-S-geranylgeranyl-L-cysteine
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
S-adenosylmethionine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys
S-adenosylhomocysteine + S-farnesyl-Leu-Ala-Arg-Tyr-Lys-Cys methyl ester
-
-
-
?
additional information
?
-
-
the ICMT isozyme catalyzes the methylation of C-terminal isoprenylcysteines
-
-
?
additional information
?
-
the ICMT isozyme catalyzes the methylation of C-terminal isoprenylcysteines
-
-
?
additional information
?
-
-
isozyme substrate specificity, no activity with N-acetyl-S-trans-geranyl-L-cysteine, overview
-
-
?
additional information
?
-
isozyme substrate specificity, no activity with N-acetyl-S-trans-geranyl-L-cysteine, overview
-
-
?
additional information
?
-
-
overexpression of the enzyme may protect against endothelial cell apoptosis by enhancing, the carboxyl methylation posttranslational modification, activity, and subsequent intracellular signalling pathway of Ras GTPase
-
-
?
additional information
?
-
-
the enzyme regulates Rac1 activity by controlling the interaction of Rac1 activity by controlling the interaction of Rac1 with Rho guanine nucleotide dissociation inhibitor, the enzyme regulates membrane accumulation and GTP loading of Rac1
-
-
?
additional information
?
-
-
inhibition of Icmt significantly decreases the activation of both RhoA and Rac1 involving Rho GDP-dissociation inhibitor, RhoGDI, overview. Icmt inhibition impairs RhoGTPase activation
-
-
?
additional information
?
-
Pseudoceratina sp.
-
isoprenylcysteine carboxyl methyltransferase methylates the carboxyl-terminal isoprenylcysteine of CAAX proteins
-
-
?
additional information
?
-
-
isoprenylcysteine carboxyl methyltransferase methylates the carboxyl-terminal isoprenylcysteine of CAAX proteins
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
NATURAL SUBSTRATE
NATURAL PRODUCT
REACTION DIAGRAM
ORGANISM
UNIPROT
COMMENTARY
(Substrate)
(Substrate)
LITERATURE
(Substrate)
(Substrate)
COMMENTARY
(Product)
(Product)
LITERATURE
(Product)
(Product)
REVERSIBILITY
r=reversible
ir=irreversible
?=not specified
r=reversible
ir=irreversible
?=not specified
S-adenosyl-L-methionine + (RhoAA) C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + (RhoA) C-terminal S-farnesyl-L-cysteine methyl ester
-
the enzyme modulates endothelial monolayer per meability by altering RhoA carboxyl methylation and activation, thus changing the organization of intercellular junctions. Carboxy methylation of RhoA may modulate endothelial barrier function
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
S-adenosyl-L-methionine + yeast a-factor mating pheromone C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + yeast a-factor mating pheromone C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
carboxyl methylation may play a role in the regulation of receptor mediated signal transduction processes in eukaryotic cells
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
reversible methylation of ras-proteins may play an important role in the modulation of their signaling properties
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
a-factor mating pheromone, Ras1 and Ras2 are putative substrates of the enzyme
-
?
S-adenosyl-L-methionine + protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + protein C-terminal S-farnesyl-L-cysteine methyl ester
-
the protein is involved in posttranslational modifications of Ras proteins
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
S-adenosyl-L-methionine + Ras protein C-terminal S-farnesyl-L-cysteine
S-adenosyl-L-homocysteine + Ras protein C-terminal S-farnesyl-L-cysteine methyl ester
-
-
-
-
?
additional information
?
-
-
the ICMT isozyme catalyzes the methylation of C-terminal isoprenylcysteines
-
-
?
additional information
?
-
the ICMT isozyme catalyzes the methylation of C-terminal isoprenylcysteines
-
-
?
additional information
?
-
-
overexpression of the enzyme may protect against endothelial cell apoptosis by enhancing, the carboxyl methylation posttranslational modification, activity, and subsequent intracellular signalling pathway of Ras GTPase
-
-
?
additional information
?
-
-
the enzyme regulates Rac1 activity by controlling the interaction of Rac1 activity by controlling the interaction of Rac1 with Rho guanine nucleotide dissociation inhibitor, the enzyme regulates membrane accumulation and GTP loading of Rac1
-
-
?
additional information
?
-
-
inhibition of Icmt significantly decreases the activation of both RhoA and Rac1 involving Rho GDP-dissociation inhibitor, RhoGDI, overview. Icmt inhibition impairs RhoGTPase activation
-
-
?
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
COFACTOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
METALS and IONS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
(2R)-2-(acetylamino)-3-[[(2Z)-3,4-diphenylbut-2-en-1-yl]sulfanyl]propanoic acid
-
15.7% inhibition at 0.01 mM
(2R)-2-(acetylamino)-3-[[(2Z)-4-(2-fluorophenyl)-3-phenylbut-2-en-1-yl]sulfanyl]propanoic acid
-
25.3% inhibition at 0.01 mM
(3,5-difluoro-4-methoxyphenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
-
-
(3-chloro-4-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
-
-
(3-chlorophenyl)-[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)ethyl]amine
-
-
(4-chloro-3-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
-
-
(5-chloro-2-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
-
-
(R)-2-(2-((benzyloxy)methyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)propanoic acid
-
-
(R)-2-(2-(phenoxymethyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R)-2-(2-(phenylthio)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R)-2-(2-benzylbenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R)-2-(2-phenoxybenzamido)-3-(((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)thio)propanoic acid
-
-
(R)-2-(3-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R)-2-(4-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R)-2-(dibenzo[b,d]furan-4-carboxamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)-propanoic acid
-
-
(R)-2-(N-methyl-2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
(R,E)-3-((3,7-dimethylocta-2,6-dien-1-yl)thio)-2-(2-phenoxybenzamido)propanoic acid
-
-
(S)-2-(2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
-
-
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(morpholin-4-ylmethyl)-1H-indole
-
-
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(piperidin-1-ylmethyl)-1H-indole
-
-
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(morpholin-4-yl)methyl]-1H-indole
-
-
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(piperidin-1-yl)methyl]-1H-indole
-
-
2'-methoxy-3',3''-diprenyl-licodione
-
isolated from Hovea parvicalyx, collected in Australia, structure determination, overview
2'-methoxy-3'-prenyllicodione
-
isolated from Hovea parvicalyx, collected in Australia, structure determination, overview
2-[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]acetamide
-
-
2-[1-[(2E,6E)-2,6-dimethylocta-2,6-dien-1-yl]-5-(3-methylphenyl)-1H-indol-3-yl]acetamide
-
-
2-[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]acetamide
-
-
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethan-1-one
-
-
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethanone
-
-
2-[5-(3-methylphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-1H-indol-3-yl]acetamide
-
-
2-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl](phenyl)amino]-1-(furan-2-yl)ethanone
-
-
3,4-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2Hpyran-4-yl)ethyl]aniline
-
-
3,5-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
-
-
3-(2,2-dimethyloxan-4-yl)-N-[(4-methoxyphenyl)methyl]-3-phenylpropan-1-amine
-
-
3-([(2E)-3-methyl-5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid
-
75% residual activity at 0.01 mM
3-([(2E)-3-methyl-5-[4-(3-methylbutyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid
-
modest inhibitor, 72% residual activity at 0.01 mM
3-([(2E)-3-methyl-5-[4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid
-
poor inhibitor, 77% residual activity at 0.01 mM
3-([(2E)-3-methyl-5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid
-
89% residual activity at 0.01 mM
3-([(2E)-3-methyl-5-[4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoic acid
-
poor inhibitor, 80% residual activity at 0.01 mM
3-([(2E)-5-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoic acid
-
poor inhibitor, 87% residual activity at 0.01 mM
3-([(2E)-5-[4-(4-tert-butylphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoic acid
-
poor inhibitor, 88% residual activity at 0.01 mM
3-chloro-4-methyl-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)ethyl]aniline
-
-
3-chloro-N-(3-chlorophenyl)-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline
-
-
3-chloro-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline
-
-
3-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-4-methylaniline
-
-
3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline
-
-
3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline
-
-
3-methoxy-N-[2-[4-(4-methoxyphenyl)-2,2-dimethyltetrahydro-2H-pyran-4-yl]ethyl]aniline
-
-
3-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
-
-
3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid
-
modest inhibitor, 53% residual activity at 0.01 mM
3-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid
-
modest inhibitor, 75% residual activity at 0.01 mM
3-[4-[(3E,7E)-4,8,12-trimethyltrideca-3,7,11-trien-1-yl]-1H-1,2,3-triazol-1-yl]propanoic acid
-
modest inhibitor, 69% residual activity at 0.01 mM
3-[[(2E)-3-methyl-5-(4-pentyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid
-
modest inhibitor, 77% residual activity at 0.01 mM
3-[[(2E)-3-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid
-
poor inhibitor, 88% residual activity at 0.01 mM
3-[[(2E)-3-methyl-5-(4-[2-[4-(thiophen-2-yl)phenyl]ethyl]-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoic acid
-
63% residual activity at 0.01 mM
3-[[(2E)-3-methyl-5-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoic acid
-
90% residual activity at 0.01 mM
3-[[(2E)-5-(4-benzyl-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
82% residual activity at 0.01 mM
3-[[(2E)-5-[4-[(biphenyl-4-yloxy)methyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
75% residual activity at 0.01 mM
3-[[(2E)-5-[4-[2-(3'-cyanobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
74% residual activity at 0.01 mM
3-[[(2E)-5-[4-[2-(4'-fluorobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
42% residual activity at 0.01 mM
3-[[(2E)-5-[4-[2-(biphenyl-3-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
74% residual activity at 0.01 mM
3-[[(2E)-5-[4-[2-(biphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoic acid
-
43% residual activity at 0.01 mM
3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]-N,N-dimethylbenzenesulfonamide
-
-
3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile
-
-
4-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3-methylaniline
-
-
4-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
-
-
4-[(naphthalen-2-yl)(thiophen-2-yl)methylidene]oxane
competitive with the prenylated peptide substrate, N-acetyl-S-farnesyl cysteine and non-competitive with SAM
4-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N-methylbenzene-1-sulfonamide
-
-
4-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]butanoic acid
-
modest inhibitor, 83% residual activity at 0.01 mM
4-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]butanoic acid
-
modest inhibitor, 90% residual activity at 0.01 mM
4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzenesulfonamide
-
-
4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile
-
-
5-(3-methylphenyl)-3-[(4-methylpiperazin-1-yl)methyl]-1-octyl-1H-indole
-
-
5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N,N-dimethylpyridin-2-amine
-
-
5-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]pentanoic acid
-
modest inhibitor, 73% residual activity at 0.01 mM
ethyl 4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]amino]benzoate
-
-
methyl 3-([(2E)-3-methyl-5-[4-(2-phenylethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate
-
69% residual activity at 0.01 mM
methyl 3-([(2E)-3-methyl-5-[4-(3-methylbutyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate
-
modest inhibitor, 77% residual activity at 0.01 mM
methyl 3-([(2E)-3-methyl-5-[4-(naphthalen-1-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate
-
poor inhibitor, 82% residual activity at 0.01 mM
methyl 3-([(2E)-3-methyl-5-[4-(phenoxymethyl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate
-
89% residual activity at 0.01 mM
methyl 3-([(2E)-3-methyl-5-[4-(thiophen-3-yl)-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl)propanoate
-
poor inhibitor, 82% residual activity at 0.01 mM
methyl 3-([(2E)-5-[4-(4-methoxyphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoate
-
poor inhibitor, 91% residual activity at 0.01 mM
methyl 3-([(2E)-5-[4-(4-tert-butylphenyl)-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl)propanoate
-
poor inhibitor, 84% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-(4-nonyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate
-
modest inhibitor, 67% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-(4-pentyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate
-
modest inhibitor, 76% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-(4-phenyl-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate
-
poor inhibitor, 89% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-(4-[2-[4-(thiophen-2-yl)phenyl]ethyl]-1H-1,2,3-triazol-1-yl)pent-2-en-1-yl]sulfanyl]propanoate
-
57% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-[4-[2-(1,1':4',1''-terphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoate
-
79% residual activity at 0.01 mM
methyl 3-[[(2E)-3-methyl-5-[4-[2-(tetrahydro-2H-pyran-2-yloxy)ethyl]-1H-1,2,3-triazol-1-yl]pent-2-en-1-yl]sulfanyl]propanoate
-
80% residual activity at 0.01 mM
methyl 3-[[(2E)-5-(4-benzyl-1H-1,2,3-triazol-1-yl)-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
80% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[(3E)-4,8-dimethylnona-3,7-dien-1-yl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
modest inhibitor, 59% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[(biphenyl-4-yloxy)methyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
67% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-(3'-cyanobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
30% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-(4'-fluorobiphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
28% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-(biphenyl-2-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
74% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-(biphenyl-3-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
65% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-(biphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
potent competitive inhibitor, 14% residual activity at 0.01 mM
methyl 3-[[(2E)-5-[4-[2-([1,1'-biphenyl]-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
-
N'-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,N-dimethylbenzene-1,3-diamine
-
-
N,N-dimethyl-1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine
-
-
N-(2-methylidenebut-3-en-1-yl)-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide
-
-
N-(2-phenoxybenzoyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
-
35.9% inhibition at 0.01 mM
N-(2-phenoxybenzoyl)-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
-
-
N-(3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]phenyl)acetamide
-
-
N-(5-methoxy-2-nitrobenzoyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
-
10.1% inhibition at 0.01 mM
N-(biphenyl-2-ylcarbonyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
-
17% inhibition at 0.01 mM
N-acetyl-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
-
19.5% inhibition at 0.01 mM
N-acetyl-S-(3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2Z,6E,10-trien-1-yl)-L-cysteine
-
competitive inhibitor of overexpressed yeast Icmt
N-acetyl-S-(E,E)-farnesyl-L-cysteine methyl ester
-
mixed-type vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine
N-acetyl-S-farnesyl-L-cysteine methylester
-
noncompetitive inhibition with respect to biotin-S-farnesyl-L-cysteine, mixed type inhibition with respect to S-adenosyl-L-methionine
N-acetyl-S-[(2E)-3-methyl-4-(4-phenoxyphenoxy)but-2-en-1-yl]-L-cysteine
-
15.5% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-4-[(naphthalen-2-ylamino)oxy]but-2-en-1-yl]-L-cysteine
-
14.5% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-5-(4-octylphenyl)pent-2-en-1-yl]-L-cysteine
-
31.1% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-5-(4-pentylphenyl)pent-2-en-1-yl]-L-cysteine
-
23.1% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-5-(4-propylphenyl)pent-2-en-1-yl]-L-cysteine
-
20.7% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-7-(4-phenoxyphenoxy)hept-2-en-1-yl]-L-cysteine
-
19.4% inhibition at 0.01 mM
N-acetyl-S-[(2E)-3-methyl-7-[(naphthalen-2-ylamino)oxy]hept-2-en-1-yl]-L-cysteine
-
22.4% inhibition at 0.01 mM
N-acetyl-S-[(2E)-4-(4-benzylphenoxy)-3-methylbut-2-en-1-yl]-L-cysteine
-
9.8% inhibition at 0.01 mM
N-acetyl-S-[(2E)-5-(4-hexylphenyl)-3-methylpent-2-en-1-yl]-L-cysteine
-
18.8% inhibition at 0.01 mM
N-acetyl-S-[(2Z)-4-(biphenyl-4-yl)-3-phenylbut-2-en-1-yl]-L-cysteine
-
26.6% inhibition at 0.01 mM
N-benzyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]furan-2-carboxamide
-
-
N-bromosuccinimide
-
56% inhibition in the presence of S-adenosyl-L-homocysteine, 87% inhibition in the absence of S-adenosyl-L-homocysteine
N-ethyl-N-([1-octyl-5-[3-(trifluoromethyl)phenyl]-1H-indol-3-yl]methyl)ethanamine
-
-
N-ethyl-N-([5-[4-(methanesulfonyl)phenyl]-1-octyl-1H-indol-3-yl]methyl)ethanamine
-
-
N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(3-fluoropyridin-4-yl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
-
-
N-ethyl-N-[[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
-
-
N-methyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]propan-2-amine
-
-
N-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,4-dimethoxyaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,5-dimethylaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethoxy)aniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethyl)aniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-isopropylaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxy-4-methylaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxyaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-(trifluoromethoxy)aniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-isopropylaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-methoxyaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,3-dimethylaniline
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N-phenylacetamide
-
-
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3,4-dimethylaniline
-
-
N-[2-(benzyloxy)benzoyl]-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
-
-
N-[3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-(2-methoxyphenyl)propyl]-N-(4-methoxybenzyl)furan-2-carboxamide
-
the inhibitor is competitive with respect to a prenylated methyl acceptor substrate but noncompetitive toward the S-adenosyl-L-methionine
N-[3-(phenylsulfonyl)propanoyl]-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
-
22.7% inhibition at 0.01 mM
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-(propan-2-yl)propan-2-amine
-
-
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-propylpropan-1-amine
-
-
Phenylglyoxal
-
74% inhibition, inhibition increases with the alkanity of the preincubation medium, S-adenosyl-L-methionine protects against inhibition
retinoic acid
-
20% decrease of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation in cells treated with 0.01 mM retinoic acid
S-[(2E)-3-[2-([1,1'-biphenyl]-4-yl)ethyl]-6-methylhepta-2,5-dien-1-yl]-N-(2-phenoxybenzoyl)-L-cysteine
-
-
S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
-
-
S-{(2E)-3-[2-(biphenyl-4-yl)ethyl]-6-methylhepta-2,5-dien-1-yl}-N-(2-phenoxybenzoyl)-L-homocysteine
-
low micromolar inhibitor
[2-(2,2-dimethyl-4-p-tolyltetrahydropyran-4-yl)ethyl]-(3-methoxyphenyl)amine
-
-
[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-(2-fluorophenyl)amine
-
-
[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(2-fluoro-4-methylphenyl)amine
-
-
[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(3-fluoro-4-methoxyphenyl)amine
-
-
[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)-ethyl]-(3-methoxyphenyl)amine
-
-
[2-[4-(3-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
-
-
[2-[4-(3-fluoro-phenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
-
-
[2-[4-(4-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
-
-
[2-[4-(4-fluorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
-
-
[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]acetic acid
-
modest inhibitor, 65% residual activity at 0.01 mM
aplysamine 6
Pseudoceratina sp.
-
i.e. (2E)-N-{2-[4-(3-aminopropoxy)-3,5-dibromophenyl]ethyl}-3-(3-bromo-4-methoxyphenyl)acrylamide
cysmethynil
-
most potent time-dependent inhibitor, inhibition of cell growth in an Icmt-dependent fashion
cysmethynil
-
specific inhibitor, is also able to inhibit Ras-mediated signaling, cell growth, and oncogenesis, and it affects cell adhesion and cell spreading
cysmethynil
-
time-dependent inhibitor, competitive inhibitor with respect to the isoprenylated cysteine substrate and a noncompetitive inhibitor with respect to S-adenosyl-L-methionine
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
shows a mix of competitive and uncompetitive inhibition
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
shows a mix of competitive and uncompetitive inhibition
N-acetyl-S-geranylgeranyl-L-cysteine
-
inhibition of N-acetyl-S-farnesyl-L-cysteine methylation
N-ethylmaleimide
-
2 mM, 94% inhibition after preincubation for 30 min, 45% inhibition in the presence of S-adenosyl-L-homocysteine
S-adenosyl-L-homocysteine
-
competitive vs. S-adenosyl-L-methionine, mixed-type vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine
S-adenosyl-L-homocysteine
-
0.2 mM, 67% inhibition of the endogenous methylation of 21000-25000 Da proteins
S-adenosyl-L-homocysteine
-
competitive inhibitor with respect to S-adenosyl-L-methionine
sinefungin
-
0.00002 mM; 50% inhibition, competitive vs. S-adenosyl-L-methionine
additional information
-
FC analogs containing larger R-groups inhibit Icmt more effectively than those with smaller R-groups, in particular, an adamantyl analog is the most potent inhibitor. Also compounds containing 3,5-disubstituted phenyl rings, with the exception of a difluoro compound, exhibit inhibitory activity, whereas the corresponding 2,4-disubstituted analogs do not
-
additional information
-
good inhibitory activity is determined largely by the characteristics of the substituent attached to the indole nitrogen, which should be a lipophilic residue with fairly wide dimensions. In contrast, the substituted phenyl ring attached to the indole ring must be of limited dimensions and lipophilicity
-
additional information
-
decrease in the length versus hydrophobicity of the indole nitrogen substituent is accompanied by loss of the time-dependent properties of this indole class of Icmt inhibitors
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ACTIVATING COMPOUND
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
formyl-methionine-leucine-phenylalanine
-
stimulation of carboxyl methylation of GTP-binding proteins through a substrate-dependent mechanism
guanosine 5'-[gamma-thio]-triphosphate
-
stimulation of 23000 Da protein methylation
guanosine 5'-[gamma-thio]-triphosphate
-
stimulation of carboxymethylation of endogenous substrates
additional information
-
no increase in N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation
-
additional information
-
no increase in methyltransferase activity in cell-free preparations by guanosine 5'-[gamma-thio]-triphosphate
-
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Carcinogenesis
Functionalized indoleamines as potent, drug-like inhibitors of isoprenylcysteine carboxyl methyltransferase (Icmt).
Carcinoma
Effects of isoprenylcysteine carboxyl methyltransferase silencing on the proliferation and apoptosis of tongue squamous cell carcinoma.
Carcinoma
Effects of isoprenylcysteine carboxylmethyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma.
Carcinoma
MicroRNA-99a-5p suppresses cell proliferation, migration, and invasion by targeting isoprenylcysteine carboxylmethyltransferase in oral squamous cell carcinoma.
Carcinoma, Squamous Cell
Effects of isoprenylcysteine carboxyl methyltransferase silencing on the proliferation and apoptosis of tongue squamous cell carcinoma.
Carcinoma, Squamous Cell
Effects of isoprenylcysteine carboxylmethyltransferase silencing on the migration and invasion of tongue squamous cell carcinoma.
Endometrial Neoplasms
Characterization of the prenylated protein methyltransferase in human endometrial carcinoma.
Hypersensitivity
Isoprenylcysteine methylation and demethylation regulate abscisic acid signaling in Arabidopsis.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Inhibition of isoprenylcysteine carboxylmethyltransferase augments BCR-ABL1 tyrosine kinase inhibition-induced apoptosis in chronic myeloid leukemia.
Leukemia, Myeloid, Acute
A Potent Isoprenylcysteine Carboxylmethyltransferase (ICMT) Inhibitor Improves Survival in Ras-Driven Acute Myeloid Leukemia.
Lymphatic Metastasis
MicroRNA-99a-5p suppresses cell proliferation, migration, and invasion by targeting isoprenylcysteine carboxylmethyltransferase in oral squamous cell carcinoma.
Nasopharyngeal Carcinoma
Isoprenylcysteine carboxylmethyltransferase is associated with nasopharyngeal carcinoma chemoresistance and Ras activation.
Neoplasm Metastasis
Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin ?3 recycling, cell migration and cancer metastasis.
Neoplasm Metastasis
MicroRNA-99a-5p suppresses cell proliferation, migration, and invasion by targeting isoprenylcysteine carboxylmethyltransferase in oral squamous cell carcinoma.
Neoplasms
A small-molecule inhibitor of isoprenylcysteine carboxyl methyltransferase with antitumor activity in cancer cells.
Neoplasms
An improved isoprenylcysteine carboxylmethyltransferase inhibitor induces cancer cell death and attenuates tumor growth in vivo.
Neoplasms
Inhibition of isoprenylcysteine carboxylmethyltransferase induces autophagic-dependent apoptosis and impairs tumor growth.
Neoplasms
Inhibition of Isoprenylcysteine carboxylmethyltransferase induces cell cycle arrest and apoptosis through p21 and p21-regulated BNIP3 induction in pancreatic cancer.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase function is essential for RAB4A-mediated integrin ?3 recycling, cell migration and cancer metastasis.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase is critical for malignant transformation and tumor maintenance by all RAS isoforms.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase is required for the impact of mutant KRAS on TAZ protein level and cancer cell self-renewal.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase regulates mitochondrial respiration and cancer cell metabolism.
Neoplasms
Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.
Neoplasms
Role of isoprenylcysteine carboxyl methyltransferase in tumor necrosis factor-alpha stimulation of expression of vascular cell adhesion molecule-1 in endothelial cells.
Neoplasms
Small-molecule inhibitors of the cancer target, isoprenylcysteine carboxyl methyltransferase, from Hovea parvicalyx.
Neoplasms
Solid-phase synthesis of Biotin-S-Farnesyl-l-Cysteine, a surrogate substrate for isoprenylcysteine Carboxylmethyltransferase (ICMT).
Neoplasms
Spermatinamine, the first natural product inhibitor of isoprenylcysteine carboxyl methyltransferase, a new cancer target.
Neoplasms
Treatment of Cancers by Inhibition of Isoprenylcysteine Carboxyl Methyltransferase.
Neoplasms
Tumor necrosis factor alpha stimulation of Rac1 activity. Role of isoprenylcysteine carboxylmethyltransferase.
Ovarian Neoplasms
Isoprenylcysteine carboxylmethyltransferase regulates ovarian cancer cell response to chemotherapy and Ras activation.
Pancreatic Neoplasms
Inhibition of Isoprenylcysteine carboxylmethyltransferase induces cell cycle arrest and apoptosis through p21 and p21-regulated BNIP3 induction in pancreatic cancer.
Progeria
Isoprenylcysteine Carboxylmethyltransferase-Based Therapy for Hutchinson-Gilford Progeria Syndrome.
protein-s-isoprenylcysteine o-methyltransferase deficiency
Isoprenylcysteine carboxyl methyltransferase deficiency in mice.
protein-s-isoprenylcysteine o-methyltransferase deficiency
Isoprenylcysteine carboxylmethyltransferase deficiency exacerbates KRAS-driven pancreatic neoplasia via Notch suppression.
Squamous Cell Carcinoma of Head and Neck
MicroRNA-99a-5p suppresses cell proliferation, migration, and invasion by targeting isoprenylcysteine carboxylmethyltransferase in oral squamous cell carcinoma.
Uterine Cervical Neoplasms
Inhibition of isoprenylcysteine carboxylmethyltransferase sensitizes common chemotherapies in cervical cancer via Ras-dependent pathway.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
KM VALUE [mM]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0059 - 0.0179
4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
0.0066
biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C10-Diazirine)-OH
-
apparent value, at pH 7.5 and 30°C
0.0278
biotin-Peg4-K(5-Fam)YIIKGVFWDPAC(C5-m-BP)-OH
-
apparent value, at pH 7.5 and 30°C
0.0146
biotin-Peg4-YIIKGVFWDPAC(C5-meta-Bp)
-
IC50 above 0.1 mM, at pH 7.5 and 25°C
0.0061
biotin-Peg4-YIIKGVFWDPAC(C5-para-Bp)
-
IC50 above 0.1 mM, at pH 7.5 and 25°C
0.0122
biotin-Peg4-YIIKGVFWDPAC(Fr)-OH
-
apparent value, at pH 7.5 and 30°C
0.594
N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine
-
-
0.0034 - 0.0183
S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
0.0059
4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
-
at pH 7.5 and 25°C
0.0179
4-benzoyl-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-L-phenylalanyl-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
-
at pH 7.5 and 25°C
0.0159
N-acetyl-S-farnesyl-L-cysteine
-
apparent value, at pH 7.5 and 30°C
0.0048
S-adenosyl-L-methionine
mutant enzyme F216Y, at pH 7.4 and 25°C
0.0067
S-adenosyl-L-methionine
wild type enzyme, at pH 7.4 and 25°C
0.0094
S-adenosyl-L-methionine
mutant enzyme F216R, at pH 7.4 and 25°C
0.018
S-adenosyl-L-methionine
mutant enzyme Y107A, at pH 7.4 and 25°C
0.022
S-adenosyl-L-methionine
mutant enzyme F216A, at pH 7.4 and 25°C
0.026
S-adenosyl-L-methionine
mutant enzyme W240A, at pH 7.4 and 25°C
0.0034
S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
-
at pH 7.5 and 25°C
0.0183
S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
-
at pH 7.5 and 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TURNOVER NUMBER [1/s]
SUBSTRATE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.93
biotin-S-farnesyl-L-cysteine
wild type enzyme, at pH 7.4 and 25°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
Ki VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0004
methyl 3-[[(2E)-5-[4-[2-(biphenyl-4-yl)ethyl]-1H-1,2,3-triazol-1-yl]-3-methylpent-2-en-1-yl]sulfanyl]propanoate
-
pH and temperature not specified in the publication
0.0354 - 0.6144
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
0.0171
N-acetyl-S-(3-(3-methylbut-2-enyl)-7,11-dimethyldodeca-2Z,6E,10-trien-1-yl)-L-cysteine
-
-
0.0026
N-acetyl-S-(E,E)-farnesyl-L-cysteine
-
competitive vs. N-acetyl-S-(E,E)-geranylgeranyl-L-cysteine
0.0023
N-acetyl-S-(E,E)-geranylgeranyl-L-cysteine
-
competitive vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine
0.0039
S-(Geranylgeranyl-2-thio)acetic acid
-
competitive vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine
0.0011
4-[(naphthalen-2-yl)(thiophen-2-yl)methylidene]oxane
substrate N-acetyl-S-farnesyl cysteine, pH not specified in the publication, temperature not specified in the publication
0.0029
4-[(naphthalen-2-yl)(thiophen-2-yl)methylidene]oxane
substrate S-adenosyl-L-methionine, pH not specified in the publication, temperature not specified in the publication
0.0022
cysmethynil
-
with respect to farnesylated and Rce1-proteolyzed K-Ras protein as substrate
0.00239
cysmethynil
-
with respect to S-adenosyl-L-methionine as substrate
0.0354
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
competitive inhibition
0.1193
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
competitive inhibition
0.3772
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
uncompetitive inhibition
0.6144
N-Acetyl-S-(3-(3-methylbut-2-enyl)-5-(4-phenyl)phenylpent-2Z-en-1-yl)-L-cysteine
-
uncompetitive inhibition
0.00207
N-acetyl-S-farnesyl-L-cysteine methyl ester
-
mixed-type vs. N-acetyl-S-farnesyl-L-cysteine
0.0021
N-acetyl-S-farnesyl-L-cysteine methyl ester
-
with respect to biotin-S-farnesyl-L-cysteine
0.00243
N-acetyl-S-farnesyl-L-cysteine methyl ester
-
with respect to S-adenosyl-L-methionine
0.005
N-acetyl-S-farnesyl-L-cysteine methyl ester
-
competitive vs. S-adenosyl-L-methionine
0.00359
S-adenosyl-L-homocysteine
-
with respect to biotin-S-farnesyl-L-cysteine
0.0044
S-adenosyl-L-homocysteine
-
mixed-type vs. N-acetyl-S-farnesyl-L-cysteine
0.00658
S-adenosyl-L-homocysteine
-
inhibition of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation
0.0115
S-adenosyl-L-homocysteine
-
inhibition of N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine
0.00645
S-adenosylethionine
-
inhibition of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation
0.0218
S-adenosylethionine
-
inhibition of N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine
0.0046
S-Farnesylthioacetic acid
-
competitive vs. N-acetyl-S-(E,E)-farnesyl-L-cysteine
0.0112
S-Farnesylthioacetic acid
-
inhibition of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation
0.0137
S-Farnesylthioacetic acid
-
competitive vs. N-acetyl-S-farnesyl-L-cysteine
0.000296
sinefungin
-
inhibition of N-acetyl-S-geranylgeranyl-L-cysteinyl-L-alanyl-S-geranylgeranyl-L-cysteine
0.000318
sinefungin
-
inhibition of N-acetyl-S-(E,E)-farnesyl-L-cysteine methylation
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
IC50 VALUE [mM]
INHIBITOR
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
IMAGE
0.0007
(1-octyl-5-m-tolyl-1H-indol-3-yl)methanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.000031
(3,5-difluoro-4-methoxyphenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000025
(3-chloro-4-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0000038
(3-chlorophenyl)-[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)ethyl]amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00047
(4-chloro-3-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000032
(5-chloro-2-fluorophenyl)-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.049
(R)-2-(2-((benzyloxy)methyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)-thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.075
(R)-2-(2-(phenoxymethyl)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.0147
(R)-2-(2-(phenylthio)benzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.038
(R)-2-(2-benzylbenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.038
(R)-2-(2-phenoxybenzamido)-3-(((2E,6E,10E)-3,7,11,15-tetramethylhexadeca-2,6,10,14-tetraen-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.21
(R)-2-(2-phenoxybenzamido)-3-(undecylthio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.0226
(R)-2-(3-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.063
(R)-2-(4-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.058
(R)-2-(dibenzo[b,d]furan-4-carboxamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)-propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.0067
(R)-2-(N-methyl-2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.149
(R,E)-3-((3,7-dimethylocta-2,6-dien-1-yl)thio)-2-(2-phenoxybenzamido)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.0078
(S)-2-(2-phenoxybenzamido)-3-(((2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl)thio)propanoic acid
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.001
1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-fluorophenyl)thiourea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-methoxphenyl)urea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
1
1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-(3-methoxyphenyl)thiourea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
1-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-3-phenylthiourea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.002
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(morpholin-4-ylmethyl)-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0021
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-(piperidin-1-ylmethyl)-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.002
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(morpholin-4-yl)methyl]-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
0.0021
1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-3-[(piperidin-1-yl)methyl]-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
1
1-(3-chlorophenyl)-3-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)thiourea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
1
1-(3-chlorophenyl)-3-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)urea
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.1
1-(3-methylbut-2-enyl)-5-m-tolyl-1H-indole
Homo sapiens
-
IC50 above 0.1 mM, in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.1
1-octyl-5-m-tolyl-1H-indole
Homo sapiens
-
IC50 above 0.1 mM, in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.03
1-octyl-5-m-tolyl-1H-indole-3-carboxamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0007
1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.005
2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-N-(3-methoxyphenyl)acetamide
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.005
2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)-N-phenylacetamide
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
2-(5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl)-N,N-diethylacetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.069
2-(5-fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-yl)acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.007
2-(5-fluoro-1-octyl-1H-indol-3-yl)acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0077
2-[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0011
2-[1-[(2E,6E)-2,6-dimethylocta-2,6-dien-1-yl]-5-(3-methylphenyl)-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-[5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl]-N,N-diethylacetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0013
2-[5-(3-ethoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0013
2-[5-(3-ethylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.069
2-[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.007
2-[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0017
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethan-1-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0017
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(4-methylpiperazin-1-yl)ethanone
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0018
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(piperidin-1-yl)ethan-1-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0018
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(piperidin-1-yl)ethanone
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0012
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(pyrrolidin-1-yl)ethan-1-one
Homo sapiens
-
pH and temperature not specified in the publication
0.0012
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]-1-(pyrrolidin-1-yl)ethanone
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0015
2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0025
2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0025
2-[5-(3-methylphenyl)-1-[[3-(trifluoromethyl)phenyl]methyl]-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00031
2-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl](phenyl)amino]-1-(furan-2-yl)ethanone
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000181
3,4-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2Hpyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00017
3,5-dichloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0012
3-(1-octyl-5-m-tolyl-1H-indol-3-yl)propanamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.001
3-chloro-4-methyl-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)ethyl]aniline
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00046
3-chloro-4-methyl-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.005
3-chloro-N-(3-chlorophenyl)-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
3-chloro-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00249
3-chloro-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000049
3-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-4-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000025
3-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00383
3-chloro-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
3-fluoro-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00325
3-fluoro-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyl-4-piperidyl)-ethyl]aniline
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0000013
3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00042
3-methoxy-N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000777
3-methoxy-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0125
3-methoxy-N-[2-[4-(4-methoxyphenyl)-2,2-dimethyltetrahydro-2H-pyran-4-yl]ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00325
3-methyl-N-[2-(4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000556
3-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.005
3-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethylamino]benzoic acid
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.005
3-[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethylamino]phenol
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00245
3-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]phenol
Homo sapiens
-
at pH 7.4 and 37°C
0.0012
3-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]propanamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00383
3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]-N,N-dimethylbenzenesulfonamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000066
3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000308
4-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00036
4-chloro-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00076
4-tert-butyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0015
4-[(naphthalen-2-yl)(thiophen-2-yl)methylidene]oxane
Homo sapiens
pH not specified in the publication, temperature not specified in the publication
0.00171
4-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N-methylbenzene-1-sulfonamide
Homo sapiens
-
at pH 7.4 and 37°C
0.0131
4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzenesulfonamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000123
4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]benzonitrile
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.03
5-(3-methylphenyl)-1-octyl-1H-indole-3-carboxamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0007
5-(3-methylphenyl)-1-octyl-3-(piperidin-1-ylmethyl)-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0005
5-(3-methylphenyl)-1-octyl-3-(pyrrolidin-1-ylmethyl)-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0007
5-(3-methylphenyl)-1-octyl-3-[(piperidin-1-yl)methyl]-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
0.0005
5-(3-methylphenyl)-1-octyl-3-[(pyrrolidin-1-yl)methyl]-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
0.0027
5-(3-methylphenyl)-3-(morpholin-4-ylmethyl)-1-octyl-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0027
5-(3-methylphenyl)-3-[(morpholin-4-yl)methyl]-1-octyl-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
0.00163
5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]-N,N-dimethylpyridin-2-amine
Homo sapiens
-
at pH 7.4 and 37°C
0.00086
5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]pyrimidin-2-amine
Homo sapiens
-
at pH 7.4 and 37°C
0.00226
5-[3-[(diethylamino)methyl]-1-octyl-1H-indol-5-yl]pyrimidine-2-carbonitrile
Homo sapiens
-
at pH 7.4 and 37°C
0.1
biotin-Peg4-YIIKGVFWDPAC(C5-meta-Bp)
Saccharomyces cerevisiae
-
IC50 above 0.1 mM, at pH 7.5 and 25°C
0.1
biotin-Peg4-YIIKGVFWDPAC(C5-para-Bp)
Saccharomyces cerevisiae
-
IC50 above 0.1 mM, at pH 7.5 and 25°C
0.00288
ethyl 4-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]amino]benzoate
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.1
ethyl [5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetate
Homo sapiens
-
IC50 above 0.1 mM, in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.000131
N'-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,N-dimethylbenzene-1,3-diamine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0008
N,N-diethyl-2-(5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl)acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0008
N,N-diethyl-2-[5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0012
N-((1-octyl-5-m-tolyl-1H-indol-3-yl)methyl)methanesulfonamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0077
N-(2-methylidenebut-3-en-1-yl)-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0194
N-(2-phenoxybenzoyl)-3-[4-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-1H-1,2,3-triazol-1-yl]-L-alanine
Homo sapiens
-
pH and temperature not specified in the publication
0.005
N-(3-chlorophenyl)-2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)acetamide
Homo sapiens
-
IC50 above 0.005 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00135
N-(3-[[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]amino]phenyl)acetamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0346
N-acetyl-S-[(2E)-3-methyl-5-(4-octylphenyl)pent-2-en-1-yl]-L-cysteine
Homo sapiens
-
pH and temperature not specified in the publication
0.00012
N-benzyl-N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]furan-2-carboxamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.067
N-ethyl-N-((1-(3-methylbut-2-enyl)-1H-indol-3-yl)methyl) ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.035
N-ethyl-N-((5-fluoro-1-(3-methylbut-2-enyl)-1H-indol-3-yl)methyl)ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.00261
N-ethyl-N-([1-octyl-5-[3-(trifluoromethyl)phenyl]-1H-indol-3-yl]methyl)ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00172
N-ethyl-N-([5-[4-(methanesulfonyl)phenyl]-1-octyl-1H-indol-3-yl]methyl)ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00442
N-ethyl-N-[(4-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.0041
N-ethyl-N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]-ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.00483
N-ethyl-N-[(5-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00222
N-ethyl-N-[(6-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00227
N-ethyl-N-[(7-fluoro-1-octyl-1H-indol-3-yl)methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.067
N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0024
N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]methyl]ethanamine
0.00175
N-ethyl-N-[[1-octyl-5-(pyridin-3-yl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00158
N-ethyl-N-[[1-octyl-5-(pyrimidin-5-yl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.00256
N-ethyl-N-[[5-(2-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.035
N-ethyl-N-[[5-(3-fluorophenyl)-1-(2-methylidenebut-3-en-1-yl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.00096
N-ethyl-N-[[5-(3-fluoropyridin-4-yl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.0018
N-[(1-octyl-5-m-tolyl-1H-indol-3-yl)methyl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0011
N-[(2E)-3,7-dimethylocta-2,6-dien-1-yl]-2-[5-(3-methylphenyl)-1-[3-(trifluoromethyl)benzyl]-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.000015
N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydropyran-4-yl)-ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.001
N-[2-(2,2,6,6-tetramethyl-4-phenyltetrahydrothiopyran-4-yl)ethyl]aniline
Homo sapiens
-
IC50 above 0.001 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0036
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-2-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000652
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,4-dimethoxyaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000054
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3,5-dimethylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00009
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethoxy)aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00038
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-(trifluoromethyl)aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00004
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-ethylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000052
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-fluoroaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000167
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-isopropylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00009
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxy-4-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000015
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methoxyaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000031
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-3-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000184
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-(trifluoromethoxy)aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000168
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-fluoroaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000132
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-isopropylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00027
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-methoxyaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000031
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-4-methylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00985
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N,3-dimethylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.01
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N-methylaniline
Homo sapiens
-
IC50 above 0.01 mM, in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00234
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]-N-phenylacetamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0027
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)-ethyl]aniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000069
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3,4-dimethylaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000026
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-3-nitroaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000682
N-[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-4-nitroaniline
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0134
N-[2-(benzyloxy)benzoyl]-S-[(2E,6E)-3,7,11-trimethyldodeca-2,6,10-trien-1-yl]-L-cysteine
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.0035
N-[3-(2,2-dimethyltetrahydro-2H-pyran-4-yl)-3-(2-methoxyphenyl)propyl]-N-(4-methoxybenzyl)furan-2-carboxamide
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0018
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0012
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]methanesulfonamide
Homo sapiens
-
pH and temperature not specified in the publication
0.00543
S-[(2E,6E)-8-(3-benzoylphenoxy)-3,7-dimethylocta-2,6-dien-1-yl]-N-([2-[2-([5-[(3aS,4S,6aR)-2-oxohexahydro-1H-thieno[3,4-d]imidazol-4-yl]pentanoyl]amino)ethoxy]ethoxy]acetyl)-D-cysteine
Homo sapiens
-
at pH 7.4 and 37°C
0.0025
S-{(2E)-3-[2-(biphenyl-4-yl)ethyl]-6-methylhepta-2,5-dien-1-yl}-N-(2-phenoxybenzoyl)-L-homocysteine
Homo sapiens
-
in 100 mM Tris-HCl, pH 7.5, at 30°C
0.00419
[2-(2,2-dimethyl-4-p-tolyltetrahydropyran-4-yl)ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00055
[2-(2,2-dimethyl-4-phenyltetrahydro-2H-pyran-4-yl)ethyl]-(2-fluorophenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0003
[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(2-fluoro-4-methylphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00016
[2-(2,2-dimethyl-4-phenyltetrahydropyran-4-yl)ethyl]-(3-fluoro-4-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000019
[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)-ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00027
[2-(2,2-dimethyl-4-thiophen-2-yltetrahydropyran-4-yl)-ethyl]phenylamine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00019
[2-[4-(3-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.000008
[2-[4-(3-fluoro-phenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.00063
[2-[4-(4-chlorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0001
[2-[4-(4-fluorophenyl)-2,2-dimethyltetrahydropyran-4-yl]-ethyl]-(3-methoxyphenyl)amine
Homo sapiens
-
in 100 mM HEPES, pH 7.5, 5 mM MgCl2, at 22°C
0.0065
2-(1-octyl-1H-indol-3-yl)acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0065
2-(1-octyl-1H-indol-3-yl)acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0018
2-(1-octyl-5-phenyl-1H-indol-3-yl)acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0018
2-(1-octyl-5-phenyl-1H-indol-3-yl)acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.001
2-[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0019
2-[5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0019
2-[5-(3-methoxyphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.033
2-[5-(3-methylphenyl)-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.033
2-[5-(3-methylphenyl)-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.001
2-[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.001
2-[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0009
5-(3-methylphenyl)-3-[(4-methylpiperazin-1-yl)methyl]-1-octyl-1H-indole
Homo sapiens
-
pH and temperature not specified in the publication
0.0009
5-(3-methylphenyl)-3-[(4-methylpiperazin-1-yl)methyl]-1-octyl-1H-indole
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0015
cysmethynil
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.076
methyl [5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetate
Homo sapiens
-
pH and temperature not specified in the publication
0.076
methyl [5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetate
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0014
N,N-diethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0014
N,N-diethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0013
N,N-dimethyl-1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0013
N,N-dimethyl-1-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0015
N,N-dimethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
pH and temperature not specified in the publication
0.0015
N,N-dimethyl-2-[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]acetamide
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0024
N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0024
N-ethyl-N-[[1-(2-methylidenebut-3-en-1-yl)-5-(3-methylphenyl)-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0006
N-ethyl-N-[[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0006
N-ethyl-N-[[5-(2-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.00161
N-ethyl-N-[[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.0041
N-ethyl-N-[[5-(3-fluorophenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0007
N-ethyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0007
N-ethyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.00218
N-ethyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
at pH 7.4 and 37°C
0.0006
N-ethyl-N-[[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
pH and temperature not specified in the publication
0.0006
N-ethyl-N-[[5-(4-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]ethanamine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0009
N-methyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]propan-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.0009
N-methyl-N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]propan-2-amine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0017
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-(propan-2-yl)propan-2-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.0017
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-(propan-2-yl)propan-2-amine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
0.0008
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-propylpropan-1-amine
Homo sapiens
-
pH and temperature not specified in the publication
0.0008
N-[[5-(3-methylphenyl)-1-octyl-1H-indol-3-yl]methyl]-N-propylpropan-1-amine
Homo sapiens
-
in 100 mM HEPES buffer pH 7.4, 5 mM MgCl2, and 0.1 mM EDTA, at 37°C
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SPECIFIC ACTIVITY [µmol/min/mg]
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
additional information
-
activities of wild-type and mutant enzymes expressed in HEK-293 cells
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE OPTIMUM
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
TEMPERATURE RANGE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
10 - 44
-
for the Escherichia coli polar lipid (control), Ste14p activity remains essentially constant when the assay temperature is maintained at 10, 16, 32, or 44°C, activity in DMPC is unchanged below (16 °C) and above (32 °C) its phase transition temperature, yielding activity levels that are the same as the Escherichia coli polar lipid values within experimental error, for C20-BAS activity is only 5% of that observed for the Escherichia coli polar lipid above (32 °C) and below (10 °C) the phase transition temperature of C20BAS
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
ORGANISM
COMMENTARY
LITERATURE
UNIPROT
SEQUENCE DB
SOURCE
-
-
-
brenda
-
485030, 485031, 485032, 485034, 485041, 485044, 485046, 658348, 659471, 672603, 672612, 674465, 676786, 704546, 705689, 706119, 718467, 719060, 719091, 719233, 720184, 720191, 733252, 733780, 734273, 734514, 734815
-
-
brenda
-
-
-
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SOURCE TISSUE
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
SOURCE
-
stably overexpressing isoprenylcysteine carboxyl methyltransferase/GFP cDNA
brenda
IHOEC cell, immortalized human ovarian epithelial cell
brenda
HPOVEC cell, primary ovarian surface epithelial cell
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
LOCALIZATION
ORGANISM
UNIPROT
COMMENTARY
GeneOntology No.
LITERATURE
SOURCE
-
Ste14p activity is lost in vesicles composed of 75-100 mol% C20BAS and 0-100 mol% C32BAS but retained in vesicles with 0-50 mol% C20BAS and 0-100 mol% C32phytBAS
brenda
-
integral membrane protein with 6 transmembrane segments, determination and analysis of membrane topology using recombinant Icmt expressed in COS-1 cells, overview
brenda
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL INFORMATION
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
malfunction
metabolism
physiological function
malfunction
-
cell migration and adhesion are impaired by enzyme inhibition (the actin cytoskeleton remains unorganized and lacks peripgeral actin filaments and stress fiber formation in the interior of the cell)
malfunction
-
enzyme inhibition reduces the function of mitochondrial oxidative phosphorylation in cancer cells. Enzyme inhibition decreases cellular ATP and depletes critical tricarboxylic acid cycle metabolites, leading to suppression of cell anabolism and growth, and marked autophagy
malfunction
reduced enzyme activity causes prelamin A mislocalization within the nucleus and triggers prelamin A-dependent activation of AKT-mammalian target of rapamycin signaling, which abolishes the premature senescence of Zmpste24-deficient fibroblasts. Enzyme inhibition increases AKT-mammalian target of rapamycin signaling and proliferation and delays senescence in Hutchinson-Gilford progeria syndrome fibroblasts
malfunction
-
reduced enzyme activity does not affect levels of prelamin A, but instead causes mislocalization of prelamin A away fromthe nuclear rim and triggers prelamin A-dependent activation of AKT-mTOR, which decreases premature senescence of zinc metallopeptidase STE24-deficient fibroblasts
metabolism
-
methylation of the C-terminus by Icmt is the final step in the prenylation pathway. The prenylation pathway consists of three enzymatic steps, the final processed protein is isoprenoid modified and methylated on the C-terminal cysteine. This protein modification pathway plays a significant role in cancer biology because many oncogenic proteins undergo prenylation
metabolism
the enzyme is involved in the farnesyl metabolism, overview
metabolism
-
the enzyme is responsible for the last common step of the posttranslational processing pathway of CaaX proteins
physiological function
isoprenylcysteine methylation and demethylation positively regulate abscisic acid signaling in Arabidopsis thaliana via feedback mechanism involving demethylation and inactivation of isoprenylated negative regulators of abscisic acid signaling
physiological function
-
isoprenylcysteine carboxylmethyltransferase plays a role in cell migration and adhesion
physiological function
-
methylation of Ras by the enzyme is required for proper localization to the plasma membrane and downstream signaling
physiological function
-
the enzyme plays an important role in the posttranslational modification of proteins involved in the regulation of cell growth and oncogenesis
physiological function
-
the enzyme regulates mitochondrial respiration and cancer cell metabolism
physiological function
ICMT loss-of-function isogenic cell lines for both RAS-transformed human mammary epithelial cells (HME1) and human cancer cell lines MiaPaca-2 and MDA-MB-231 containing naturally occurring mutant KRAS. In both in vitro and in vivo tumorigenesis studies, ICMT loss-of-function abolishes the tumor initiation ability of all major isoforms of mutant RAS in HME1 cells, and the tumor maintenance capacity of MiaPaca-2 and MDA-MB-231 cells
Show AA Sequence and Transmembrane Helices (4303 entries)
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please use the AA Sequence and Transmembrane Helices Search for a specific query.
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PDB
SCOP
CATH
UNIPROT
ORGANISM
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
MOLECULAR WEIGHT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
86000
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
SUBUNIT
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
homodimer
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
PROTEIN VARIANTS
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
F216A
the mutant shows reduced activity compared to the wild type enzyme
F216R
the mutant shows reduced activity compared to the wild type enzyme
W240A
the mutant shows reduced activity compared to the wild type enzyme
Y107A
the mutant shows reduced activity compared to the wild type enzyme
D122A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
E107A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
E142A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
E146A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
E251A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
E252A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
F124A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
F124R
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
F258A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
F72A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
P275A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
R209A
-
site-directed mutagenesis, the mutant shows activity similar to the wild-type enzyme, comparison of membrane topology
R63A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
RH209/210A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
S123A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
W241A
-
site-directed mutagenesis, the mutant shows decreased activity compared to the wild-type enzyme, comparison of membrane topology
Y266A
-
site-directed mutagenesis, the mutant shows increased activity comapred to the wild-type enzyme, comparison of membrane topology
E167A
-
the mutation leads to strongly reduced activity compared to the wild type enzyme
H113A
-
the mutation leads to strongly reduced activity compared to the wild type enzyme
H126A
-
the mutation leads to strongly reduced activity compared to the wild type enzyme
R163A
-
the mutation leads to strongly reduced activity compared to the wild type enzyme
E213Q
-
the mutant is enzymatically almost inactive (5% activity compared to the wild type)
L81F
-
the mutant shows little to no in vitro methyltransferase activity
additional information
additional information
-
transgenic plants overproducing ICME exhibit abscisic acid hypersensitivity in stomatal closure and seed germination assays. Induction leads to demethylation and inactivation of isoprenylated negative regulators of abscisic acid signaling
additional information
transgenic plants overproducing ICME exhibit abscisic acid hypersensitivity in stomatal closure and seed germination assays. Induction leads to demethylation and inactivation of isoprenylated negative regulators of abscisic acid signaling
additional information
-
construction of various CFP-Icmt C-terminal truncation mutants, overview, comparison of membrane topology
additional information
-
enzyme knockout by siRNA in MDA-MB 231 cells, phenotype, overview
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
pH STABILITY
ORGANISM
UNIPROT
COMMENTARY
LITERATURE
Please wait a moment until the data is sorted. This message will disappear when the data is sorted.
GENERAL STABILITY
ORGANISM
UNIPROT
LITERATURE
complete loss of activity after exposure to detergent